JP2019518713A - 癌療法のための改変ｔｒａｉｌ - Google Patents

癌療法のための改変ｔｒａｉｌ Download PDF

Info

Publication number
JP2019518713A
JP2019518713A JP2018548878A JP2018548878A JP2019518713A JP 2019518713 A JP2019518713 A JP 2019518713A JP 2018548878 A JP2018548878 A JP 2018548878A JP 2018548878 A JP2018548878 A JP 2018548878A JP 2019518713 A JP2019518713 A JP 2019518713A
Authority
JP
Japan
Prior art keywords
trail
seq
polypeptide
amino acid
another embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018548878A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518713A5 (enExample
Inventor
ダイアナ フン−イ チャイ マルカントニオ，
ダイアナ フン−イ チャイ マルカントニオ，
スティーブン エル． サジンスキー，
スティーブン エル． サジンスキー，
ビルギット エム． ショーベール，
ビルギット エム． ショーベール，
エリック エム． タム，
エリック エム． タム，
Original Assignee
メリマック ファーマシューティカルズ インコーポレーティッド
メリマック ファーマシューティカルズ インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メリマック ファーマシューティカルズ インコーポレーティッド, メリマック ファーマシューティカルズ インコーポレーティッド filed Critical メリマック ファーマシューティカルズ インコーポレーティッド
Publication of JP2019518713A publication Critical patent/JP2019518713A/ja
Publication of JP2019518713A5 publication Critical patent/JP2019518713A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018548878A 2016-03-16 2017-03-16 癌療法のための改変ｔｒａｉｌ Pending JP2019518713A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662309352P 2016-03-16 2016-03-16
US62/309,352 2016-03-16
US201662323501P 2016-04-15 2016-04-15
US62/323,501 2016-04-15
US201762445556P 2017-01-12 2017-01-12
US62/445,556 2017-01-12
PCT/US2017/022789 WO2017161173A1 (en) 2016-03-16 2017-03-16 Engineered trail for cancer therapy

Publications (2)

Publication Number Publication Date
JP2019518713A true JP2019518713A (ja) 2019-07-04
JP2019518713A5 JP2019518713A5 (enExample) 2020-04-23

Family

ID=58413224

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018548878A Pending JP2019518713A (ja) 2016-03-16 2017-03-16 癌療法のための改変ｔｒａｉｌ

Country Status (10)

Country Link
US (1) US20190077870A1 (enExample)
EP (1) EP3430034A1 (enExample)
JP (1) JP2019518713A (enExample)
KR (1) KR20180127407A (enExample)
CN (1) CN108884142A (enExample)
AU (1) AU2017234679A1 (enExample)
CA (1) CA3017622A1 (enExample)
IL (1) IL261267A (enExample)
MX (1) MX2018011219A (enExample)
WO (1) WO2017161173A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108026181B (zh) * 2015-10-22 2021-07-02 成都华创生物技术有限公司 一种TRAIL双靶点突变蛋白MuR6S4TR、其制备方法及其应用
KR20190017804A (ko) * 2016-06-13 2019-02-20 메리맥 파마슈티컬즈, 인크. 환자를 선별하고 trail-기반 치료제 또는 사멸 수용체 효능제로 치료하는 방법
CN109125709B (zh) * 2018-08-23 2021-10-22 成都华创生物技术有限公司 Trail突变体在制备治疗痤疮药物中的应用及一种制剂
KR102764218B1 (ko) * 2020-10-13 2025-02-11 신동준 반려견의 항암용 재조합 단백질 및 이를 포함하는 반려견을 위한 항암용 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007532480A (ja) * 2003-12-05 2007-11-15 ユニバーシティ オブ フローニンゲン 改良されたサイトカインの設計
JP2014511679A (ja) * 2011-04-01 2014-05-19 ウニヴェルズィテート シュトゥットガルト 抗体結合ドメインを有する組換えｔｎｆリガンドファミリーメンバーポリペプチドおよびそれらの使用
JP2014520510A (ja) * 2011-07-06 2014-08-25 常州▲ば▼標生物医薬研究所有限公司 腫瘍ターゲティング腫瘍壊死因子関連アポトーシス誘導リガンド変異体及びその応用
JP2014230545A (ja) * 2008-07-21 2014-12-11 アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ Ｔｎｆｓｆ一本鎖分子
WO2015164588A1 (en) * 2014-04-23 2015-10-29 Abbvie, Inc. Single-chain trail-receptor agonist proteins
WO2016146818A1 (en) * 2015-03-18 2016-09-22 Universität Stuttgart Single-chain tnf ligand family molecules and fusion proteins and derivatives thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
JPH0822239B2 (ja) * 1988-07-07 1996-03-06 株式会社蛋白工学研究所 変異ヒト腫傷壊死因子
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
JP5118796B2 (ja) * 1999-06-28 2013-01-16 ジェネンテック， インコーポレイテッド 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
JP4459810B2 (ja) 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
CA2499816C (en) 2002-09-27 2013-07-30 Xencor, Inc. Optimized fc variants and methods for their generation
AU2003286467B2 (en) 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
CA2552788C (en) 2004-01-12 2013-09-24 Applied Molecular Evolution, Inc. Fc region variants
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
GB0724532D0 (en) * 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
US20120134984A1 (en) * 2009-06-01 2012-05-31 Olga Lubman Molecules with extended half-lives and uses thereof
WO2011139681A1 (en) 2010-04-26 2011-11-10 Merrimack Pharmaceuticals Assays for anti-drug antibodies in the presence of abundant endogenous protein counterpart of the drug
EP2468764A1 (en) * 2010-12-24 2012-06-27 Rijksuniversiteit te Groningen TNF family ligand variants

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007532480A (ja) * 2003-12-05 2007-11-15 ユニバーシティ オブ フローニンゲン 改良されたサイトカインの設計
JP2014230545A (ja) * 2008-07-21 2014-12-11 アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ Ｔｎｆｓｆ一本鎖分子
JP2014511679A (ja) * 2011-04-01 2014-05-19 ウニヴェルズィテート シュトゥットガルト 抗体結合ドメインを有する組換えｔｎｆリガンドファミリーメンバーポリペプチドおよびそれらの使用
JP2014520510A (ja) * 2011-07-06 2014-08-25 常州▲ば▼標生物医薬研究所有限公司 腫瘍ターゲティング腫瘍壊死因子関連アポトーシス誘導リガンド変異体及びその応用
WO2015164588A1 (en) * 2014-04-23 2015-10-29 Abbvie, Inc. Single-chain trail-receptor agonist proteins
WO2016146818A1 (en) * 2015-03-18 2016-09-22 Universität Stuttgart Single-chain tnf ligand family molecules and fusion proteins and derivatives thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SEIFERT O. ET AL., MOL. CANCER THER., vol. 13(1)(2014), JPN6021007491, pages 101 - 111, ISSN: 0004608690 *

Also Published As

Publication number Publication date
IL261267A (en) 2018-10-31
US20190077870A1 (en) 2019-03-14
WO2017161173A1 (en) 2017-09-21
CA3017622A1 (en) 2017-09-21
EP3430034A1 (en) 2019-01-23
MX2018011219A (es) 2019-01-10
AU2017234679A1 (en) 2018-08-30
KR20180127407A (ko) 2018-11-28
CN108884142A (zh) 2018-11-23

Similar Documents

Publication Publication Date Title
JP7587656B2 (ja) Ｐｄ－ｌ１及びｃｄ１３７に結合する抗体分子
CN112512581B (zh) 针对cldn18.2和cd3的抗体构建体
AU2019301206B2 (en) Antibody molecules that bind CD137 and OX40
JP7148539B2 (ja) 免疫抱合体
US9458245B2 (en) ANTI-C-MET tandem Fc bispecific antibodies
KR20210091710A (ko) PD-1 표적화 IL-15/IL-15Rα Fc 융합 단백질 및 병용요법에서의 이의 용도
JP2021520805A (ja) ４−１ＢＢＬを含むＨｅｒ２標的化抗原結合分子
JP2020518622A (ja) Ｏｘ４０およびｃｔｌａ−４に対する二重特異性抗体
US20250051413A1 (en) Chimeric molecules comprising il-12 agonist polypeptide
CA3188215A1 (en) Proteins binding nkg2d, cd16 and egfr
JP2019518713A (ja) 癌療法のための改変ｔｒａｉｌ
US20240209106A1 (en) Anti-cd137 antibodies and methods of use
WO2021078123A1 (en) RECOMBINANT PROTEIN TARGETING PD-1 AND TGFβ
CN111164101B (zh) 甲状腺素视黄质运载蛋白免疫球蛋白融合体
TW202417483A (zh) 結合nkg2d、cd16及ceacam5之蛋白質
CN120112558A (zh) 治疗慢性病毒感染的含cd8抗原结合分子的融合物
US20240209113A1 (en) Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use
EA048596B1 (ru) Антитела, которые связывают psma и гамма-дельта рецепторы т-клеток
HK40037072A (en) Fc binding fragments comprising a pd-l1 antigen-binding site

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200312

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210304

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211006